Biomea Fusion, Inc. (BMEA)
| Market Cap | 110.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.80M |
| Shares Out | 72.30M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,229,692 |
| Open | 1.720 |
| Previous Close | 1.730 |
| Day's Range | 1.530 - 1.745 |
| 52-Week Range | 0.872 - 3.080 |
| Beta | -0.27 |
| Analysts | Strong Buy |
| Price Target | 9.83 (+542.48%) |
| Earnings Date | May 12, 2026 |
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price target is $9.83, which is an increase of 542.48% from the latest price.
News
Biomea Fusion Transcript: Study result
Top-line results from the COVALENT-112 study show that icovamenib, a menin inhibitor, led to a 52% increase in C-peptide at 12 weeks and sustained beta cell function at 52 weeks in recent-onset type 1 diabetes, with a favorable safety profile. A phase II study will further evaluate extended dosing and combination strategies.
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced...
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26...
Biomea Fusion Transcript: Fireside chat
Icovamenib, a novel menin inhibitor, shows promise in restoring beta cell function and reducing A1C in diabetes patients, especially those failing GLP-1 therapies. Ongoing trials aim for key data by year-end, with the potential to delay insulin dependence and reshape diabetes treatment.
Biomea Fusion Transcript: Fireside chat
The discussion highlighted imminent phase I data for BMF-650, designed for improved oral bioavailability and tolerability in obesity, and icovamenib's novel approach to restoring beta cell function in diabetes. Key clinical milestones are expected in Q2 and Q4, with a cash runway into 2027.
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported ...
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026
The company is advancing two in-house assets for diabetes and obesity, including a novel menin inhibitor with durable effects and an oral GLP-1 agent designed for better adherence. Key clinical data readouts are expected in 2024, with phase III planning underway.
Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Two oral candidates are advancing: Icovamenib for insulin-deficient and GLP-1-failing diabetes patients, and BMF-650 for weight loss. Icovamenib shows durable A1C reduction post-treatment, with phase II trials underway and key data expected by year-end and Q4 2026.
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced...
Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing two main assets for diabetes and obesity, with icovamenib showing durable A1C reductions and BMF-650 progressing in early clinical trials. Two phase II studies are set to enroll in Q1, with key data expected in Q4, and the cash runway extends into early 2027.
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-li...
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D.
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd ...
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing Menin-targeted and oral GLP-1 therapies for diabetes and obesity, with phase II trials focusing on key patient subgroups and a phase I oral GLP-1 study targeting better tolerability. Financial runway extends into 2027, with partnering under consideration.
Biomea Fusion Transcript: Piper Sandler 37th Annual Healthcare Conference
Biotech innovation is fueling a sector rebound, with new therapies targeting diabetes' root causes. Menin inhibition shows promise for insulin-deficient patients, and an oral GLP-1 agonist aims to improve tolerability. Key data readouts and potential pharma partnerships are expected soon.
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on N...
Biomea Fusion Transcript: Jefferies London Healthcare Conference 2025
The discussion highlighted a strategic focus on insulin-deficient diabetes and obesity, with icovamenib showing strong safety and efficacy in restoring beta cell function. Phase II trials are progressing rapidly, and the pipeline includes a next-gen oral GLP-1 agonist with promising preclinical results.
Biomea Fusion to Participate at Jefferies London Healthcare Conference
SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
SAN CARLOS, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today an...
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea's next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) rec...
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poste...
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today an...